NDC 50458-611

INVEGA HAFYERA

Paliperidone Palmitate

INVEGA HAFYERA is a Intramuscular Injection, Suspension, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Janssen Pharmaceuticals, Inc. The primary component is Paliperidone Palmitate.

Product ID50458-611_3210fa9c-9331-45af-8ee2-e0aa9e3011fd
NDC50458-611
Product TypeHuman Prescription Drug
Proprietary NameINVEGA HAFYERA
Generic NamePaliperidone Palmitate
Dosage FormInjection, Suspension, Extended Release
Route of AdministrationINTRAMUSCULAR
Marketing Start Date2021-08-30
Marketing CategoryNDA /
Application NumberNDA207946
Labeler NameJanssen Pharmaceuticals, Inc
Substance NamePALIPERIDONE PALMITATE
Active Ingredient Strength700 mg/3.5mL
Pharm ClassesAtypical Antipsychotic [EPC]
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 50458-611-01

1 SYRINGE in 1 CARTON (50458-611-01) > 3.5 mL in 1 SYRINGE
Marketing Start Date2021-08-30
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "INVEGA HAFYERA" or generic name "Paliperidone Palmitate"

NDCBrand NameGeneric Name
50458-560INVEGA SUSTENNApaliperidone palmitate
50458-561INVEGA SUSTENNApaliperidone palmitate
50458-562INVEGA SUSTENNApaliperidone palmitate
50458-563INVEGA SUSTENNApaliperidone palmitate
50458-564INVEGA SUSTENNApaliperidone palmitate
50458-606INVEGA TRINZApaliperidone palmitate
50458-607INVEGA TRINZApaliperidone palmitate
50458-608INVEGA TRINZApaliperidone palmitate

Trademark Results [INVEGA HAFYERA]

Mark Image

Registration | Serial
Company
Trademark
Application Date
INVEGA HAFYERA
INVEGA HAFYERA
88768753 not registered Live/Pending
JOHNSON & JOHNSON
2020-01-22
© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.